Tech Company Financing Transactions

YmAbs Therapeutics Funding Round

HBM Healthcare Investments and private investors participated in a $50 million funding round for YmAbs Therapeutics. The financing was recorded on 10/25/2017.

Transaction Overview

Company Name
Announced On
10/25/2017
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Undisclosed
Investors
Proceeds Purpose
This funding is an important financial achievement for YmAbs, and enables us to focus on bringing our lead compounds, burtomab and naxitamab, through the final steps of the regulatory pathway towards approval.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
230 Park Ave. 3350
New York, NY 10169
USA
Email Address
Overview
YmAbs Therapeutics is a clinical stage biopharmaceutical company focused on developing new cancer treatments through immunotherapies. Our lead antibody programs target GD2 and B7-H3. In addition, YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies.
Profile
YmAbs Therapeutics LinkedIn Company Profile
Social Media
YmAbs Therapeutics Company Twitter Account
Company News
YmAbs Therapeutics News
Facebook
YmAbs Therapeutics on Facebook
YouTube
YmAbs Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Claus Moller
  Claus Moller LinkedIn Profile  Claus Moller Twitter Account  Claus Moller News  Claus Moller on Facebook
Chief Financial Officer
Bo Kruse
  Bo Kruse LinkedIn Profile  Bo Kruse Twitter Account  Bo Kruse News  Bo Kruse on Facebook
Chief Medical Officer
Steen Lisby
  Steen Lisby LinkedIn Profile  Steen Lisby Twitter Account  Steen Lisby News  Steen Lisby on Facebook
Chief Operating Officer
Joris Wilms
  Joris Wilms LinkedIn Profile  Joris Wilms Twitter Account  Joris Wilms News  Joris Wilms on Facebook
President
Thomas Gad
  Thomas Gad LinkedIn Profile  Thomas Gad Twitter Account  Thomas Gad News  Thomas Gad on Facebook
VP - Operations
Torben Lund-Hansen
  Torben Lund-Hansen LinkedIn Profile  Torben Lund-Hansen Twitter Account  Torben Lund-Hansen News  Torben Lund-Hansen on Facebook


 

 

Browse more venture capital transactions:

Prev: 10/25/2017: OpenIO venture capital transaction
Next: 10/25/2017: NeuroPace venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary